Updates
** Shares of drugmaker Corcept Therapeutics CORT.O soars as much as 91.7% to record high of $104.73
** Stock last up 83.6% at $100.29
** CORT says its experimental drug for ovarian cancer in combination with chemotherapy met the main goal of a late-stage trial
** Co says the drug, relacorilant, when combined with chemotherapy agent nab-paclitaxel, showed a 30% reduction in disease-progression risk in platinum-resistant ovarian cancer patients, compared with those treated with chemotherapy alone
** Canaccord Genuity analyst Edward Nash estimates peak sales of $1.3 billion for relacorilant by 2036
** Platinum-resistant ovarian cancer is a type of ovarian cancer that doesn't respond to platinum-based chemotherapy treatments, which are typically used as a first-line therapy
** Including session's moves, CORT shares more than double YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。